Abstract
Type 2 (non-insulin-dependent) diabetes mellitus afflicts millions of people worldwide and is one of the main causes of morbidity and mortality. Current therapeutic agents to treat Type 2 diabetes are insufficient and thus, newer approaches are desperately needed. Type 2 diabetes is manifested by progressive metabolic impairments in tissues such as skeletal muscle, adipose tissue and liver, such that these tissues become less responsive to insulin. Skeletal muscle is quantitatively the most important tissue involved in maintaining glucose homeostasis under insulin-stimulated conditions, and is a major site of insulin resistance in Type 2 diabetic patients. At the cellular level, glucose transport into skeletal muscle is the rate-limiting step for whole body glucose uptake and a primary site of insulin resistance in Type 2 diabetes. Thus, skeletal muscle is a key insulin target tissue that harbours intrinsic defects that impinges upon whole body glucose homeostasis. Here, we review the current knowledge of signalling events that regulate glucose transport in human skeletal muscle.
Keywords: adipose tissue, glucose transport, insulin resistance, insulin signalling, obesity, skeletal muscle, type (non-insulin dependent) diabetes mellitus
Current Diabetes Reviews
Title: Molecular Mechanisms of Skeletal Muscle Insulin Resistance in Type 2 Diabetes
Volume: 1 Issue: 2
Author(s): Karim Bouzakri, Heikki A. Koistinen and Juleen R. Zierath
Affiliation:
Keywords: adipose tissue, glucose transport, insulin resistance, insulin signalling, obesity, skeletal muscle, type (non-insulin dependent) diabetes mellitus
Abstract: Type 2 (non-insulin-dependent) diabetes mellitus afflicts millions of people worldwide and is one of the main causes of morbidity and mortality. Current therapeutic agents to treat Type 2 diabetes are insufficient and thus, newer approaches are desperately needed. Type 2 diabetes is manifested by progressive metabolic impairments in tissues such as skeletal muscle, adipose tissue and liver, such that these tissues become less responsive to insulin. Skeletal muscle is quantitatively the most important tissue involved in maintaining glucose homeostasis under insulin-stimulated conditions, and is a major site of insulin resistance in Type 2 diabetic patients. At the cellular level, glucose transport into skeletal muscle is the rate-limiting step for whole body glucose uptake and a primary site of insulin resistance in Type 2 diabetes. Thus, skeletal muscle is a key insulin target tissue that harbours intrinsic defects that impinges upon whole body glucose homeostasis. Here, we review the current knowledge of signalling events that regulate glucose transport in human skeletal muscle.
Export Options
About this article
Cite this article as:
Bouzakri Karim, Koistinen A. Heikki and Zierath R. Juleen, Molecular Mechanisms of Skeletal Muscle Insulin Resistance in Type 2 Diabetes, Current Diabetes Reviews 2005; 1 (2) . https://dx.doi.org/10.2174/1573399054022785
DOI https://dx.doi.org/10.2174/1573399054022785 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharma-metabolomics in Neonatology: is it a Dream or a Fact?
Current Pharmaceutical Design The Diabetic Foot
Current Pharmaceutical Design Genetic Insights into Sepsis: What have we Learned and How will it Help?
Current Pharmaceutical Design Evaluation of Thiol/Disulfide Homeostasis in Pediatric Patients with Diabetic Ketoacidosis
Combinatorial Chemistry & High Throughput Screening The Woman’s Heart: Insights into New Potential Targeted Therapy
Current Medicinal Chemistry Impact of the CD40-CD40L Dyad in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets AGE-RAGE System and Carcinogenesis
Current Pharmaceutical Design Weight Gain and Metabolic Changes During Treatment with Antipsychotics and Antidepressants
Endocrine, Metabolic & Immune Disorders - Drug Targets Metabolic Correction in the Management of Diabetic Peripheral Neuropathy: Improving Clinical Results Beyond Symptom Control
Current Clinical Pharmacology Impact of Aging on the Angiogenic Potential of the Myocardium: Implications for Angiogenic Therapies with Emphasis on Sirtuin Agonists
Recent Patents on Cardiovascular Drug Discovery Cardiac Morbidity in an HIV-1 Lipodystrophy Patient Cohort Expressing the TNF-α-238 G/A Single Nucleotide Gene Polymorphism
Current HIV Research Antidiabetic Drugs and the Kidney
Current Pharmaceutical Design Gene Therapy for Diabetes Mellitus
Current Molecular Medicine Processing and Regulation Mechanisms within Antigen Presenting Cells: A Possibility for Therapeutic Modulation
Current Pharmaceutical Design Epidemiology of Diabetes Mellitus in the United Arab Emirates
Current Diabetes Reviews Disruption of Metabolic Pathways - Perspectives for the Treatment of Cancer
Current Cancer Drug Targets Withdrawal Notice: Ionic Liquid Mediated Synthesis of Schiff bases Bearing Thiazole and Indole Moieties
Current Organic Synthesis Iron Overload is Associated with Perihematoma Edema Growth Following Intracerebral Hemorrhage that may Contribute to In-hospital Mortality and Long-term Functional Outcome
Current Neurovascular Research Preconception Counselling: A Five- Year Experience in a Teratology Information Service
Letters in Drug Design & Discovery New Insights on the Xenobiotic-Sensing Nuclear Receptors in Liver Diseases – CAR and PXR-
Current Drug Metabolism